What is LIANY stock price today?

LIANY (Lianbio) stock is trading at $0.12 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is LIANY stock going up or down today?

LIANY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy LIANY stock now?

The decision to buy LIANY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is LIANY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for LIANY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is LIANY stock overvalued or undervalued?

Use our DCF valuation calculator to determine if LIANY is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is LIANY's P/E ratio?

P/E ratio data for LIANY will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is LIANY's market cap?

LIANY (Lianbio) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is LIANY's price to book ratio?

LIANY trades at a price-to-book (P/B) ratio of 0.04, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does LIANY pay dividends?

LIANY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is LIANY's dividend yield?

LIANY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is LIANY stock a good long-term investment?

LIANY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is LIANY's revenue growth rate?

Revenue growth data for LIANY is available on our dashboard with detailed financial statement analysis.

Profitability metrics for LIANY are available on our dashboard with complete income statement analysis.

What are the risks of investing in LIANY?

Key risks for LIANY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does LIANY compare to its competitors?

Compare LIANY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize LIANY's performance and positioning.

What is LIANY's stock price target for 2026?

Our AI model provides price targets for LIANY based on fundamental analysis: Bull case $0.16 (+30%), Base case $0.14 (+15%), Bear case $0.11 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about LIANY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for LIANY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is LIANY's next earnings report?

LIANY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

LIANY - Lianbio

NYSE * Health Care * Biotechnology

$0.12

+$0.00 (+0.00%)

About Lianbio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LIANY Key Statistics

Market Cap

$13.31M

P/B Ratio

0.04

EPS

$-1.52

Employees

163

How LIANY Compares to Peers

LIANY is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
LIANY(This stock)	$13.31M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Lianbio Company Information

Headquarters: New Jersey; U.S.A
Website: www.lianbio.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 17, 2026 at 11:42 PM EDT

Ready to invest in LIANY?

Commission-free trading available. Affiliate links.

LIANY Lician Score

5% confidence

4.0/10

Neutral

LIANY has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates LIANYacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

LIANY Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for LIANY

Dashboard

Enter a ticker to analyze